TW201642860A - 布羅莫結構域抑制劑 - Google Patents

布羅莫結構域抑制劑 Download PDF

Info

Publication number
TW201642860A
TW201642860A TW105112168A TW105112168A TW201642860A TW 201642860 A TW201642860 A TW 201642860A TW 105112168 A TW105112168 A TW 105112168A TW 105112168 A TW105112168 A TW 105112168A TW 201642860 A TW201642860 A TW 201642860A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
compound
methylsulfonylphenyl
cyclopropylmethoxy
methylisoquinolin
Prior art date
Application number
TW105112168A
Other languages
English (en)
Chinese (zh)
Inventor
貝坦科特胡安曼努爾
史塔福德傑佛瑞艾倫
史丹斯菲爾德萊恩
維爾詹姆士馬文
Original Assignee
塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 塞爾基因定量細胞研究公司 filed Critical 塞爾基因定量細胞研究公司
Publication of TW201642860A publication Critical patent/TW201642860A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW105112168A 2015-04-22 2016-04-19 布羅莫結構域抑制劑 TW201642860A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
TW201642860A true TW201642860A (zh) 2016-12-16

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105112168A TW201642860A (zh) 2015-04-22 2016-04-19 布羅莫結構域抑制劑

Country Status (22)

Country Link
US (1) US20160310423A1 (enExample)
EP (1) EP3285770A4 (enExample)
JP (1) JP2018513863A (enExample)
KR (1) KR20170139119A (enExample)
CN (1) CN107613981A (enExample)
AR (1) AR104340A1 (enExample)
AU (1) AU2016252992A1 (enExample)
BR (1) BR112017022691A2 (enExample)
CA (1) CA2983446C (enExample)
CL (1) CL2017002679A1 (enExample)
CO (1) CO2017011482A2 (enExample)
EA (1) EA201792317A1 (enExample)
EC (1) ECSP17071545A (enExample)
HK (1) HK1243948A1 (enExample)
IL (1) IL255120B (enExample)
MX (2) MX390077B (enExample)
PE (1) PE20180036A1 (enExample)
PH (1) PH12017501933A1 (enExample)
SG (1) SG11201708627TA (enExample)
TW (1) TW201642860A (enExample)
WO (1) WO2016172618A1 (enExample)
ZA (1) ZA201707186B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂
HUE058289T2 (hu) 2016-10-27 2022-07-28 Celgene Quanticel Res Inc Brómdomén és extraterminális protein inhibitor kombinációs terápia
AU2019309693B2 (en) * 2018-07-23 2023-03-16 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor
EP4294397A1 (en) * 2021-02-22 2023-12-27 Celgene Quanticel Research, Inc. Bromodomain (bet) inhibitor for use in treating prostate cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP3290407B1 (en) * 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂

Also Published As

Publication number Publication date
IL255120B (en) 2021-03-25
CL2017002679A1 (es) 2018-05-25
PH12017501933A1 (en) 2018-03-19
MX390077B (es) 2025-03-20
KR20170139119A (ko) 2017-12-18
MX2020010899A (es) 2022-02-15
WO2016172618A1 (en) 2016-10-27
JP2018513863A (ja) 2018-05-31
CA2983446C (en) 2024-04-09
HK1243948A1 (zh) 2018-07-27
NZ736630A (en) 2024-03-22
IL255120A0 (en) 2017-12-31
CN107613981A (zh) 2018-01-19
CA2983446A1 (en) 2016-10-27
CO2017011482A2 (es) 2018-01-31
EA201792317A1 (ru) 2018-03-30
MX2017013501A (es) 2018-02-09
EP3285770A4 (en) 2018-10-31
ECSP17071545A (es) 2017-12-01
BR112017022691A2 (pt) 2018-07-17
AU2016252992A1 (en) 2017-11-09
EP3285770A1 (en) 2018-02-28
AR104340A1 (es) 2017-07-12
MX377159B (es) 2025-03-07
PE20180036A1 (es) 2018-01-09
SG11201708627TA (en) 2017-11-29
US20160310423A1 (en) 2016-10-27
ZA201707186B (en) 2019-01-30

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
JP2024056905A (ja) ブロモドメイン阻害剤
US20230301983A1 (en) Bromodomain inhibitor
CA3140412A1 (en) Compound for treating gout or hyperuricemia
JP2022510303A (ja) 痛風または高尿酸血症を処置または予防するための方法
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP2581374B1 (en) Preparation of tetrahydropyrido[4,3-b]indole derivatives
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EA043666B1 (ru) Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии